Innoviva (Innoviva) Total Liabilities : $568.6 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Innoviva Total Liabilities?

Innoviva's Total Liabilities for the quarter that ended in Dec. 2023 was $568.6 Mil.

Innoviva's quarterly Total Liabilities declined from Jun. 2023 ($563.15 Mil) to Sep. 2023 ($560.61 Mil) but then increased from Sep. 2023 ($560.61 Mil) to Dec. 2023 ($568.55 Mil).

Innoviva's annual Total Liabilities increased from Dec. 2021 ($400.46 Mil) to Dec. 2022 ($665.71 Mil) but then declined from Dec. 2022 ($665.71 Mil) to Dec. 2023 ($568.55 Mil).

Innoviva Total Liabilities Historical Data

The historical data trend for Innoviva's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Total Liabilities Chart

Innoviva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

382.71

391.73

400.46

665.71

568.55

Innoviva Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															665.71	568.28	563.15	560.61	568.55

Innoviva Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Innoviva's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	38.134	+	(447.869	+	12.11
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	70.439	+	0)
	=	568.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1243.507	-	674.955
	=	568.6

Innoviva's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	38.134	+	(447.869	+	12.11
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	70.439	+	0)
	=	568.6

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1243.507	-	674.955
	=	568.6

Innoviva Total Liabilities Related Terms

Thank you for viewing the detailed overview of Innoviva's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Innoviva (Innoviva) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HVE:Germany HVE:Germany

Address

1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010

Website

https://www.inva.com

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Executives

Marianne Zhen	officer: Chief Accounting Officer	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso	officer: Chief Financial Officer	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel	officer: Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx	director	3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld	officer: Chief Executive Officer	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava	director	C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards	officer: CEO of La Jolla Pharmaceutical	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511